MYB and MYC transcripts have been identified as the downstream target of METTL14, increasing their stability and translation.[29] METTL14 is associated with hepatocellular carcinoma (HCC) cell dedifferentiation and cancer stem cell (CSC) generation conferring resistance to chemotherapeutics. Here, METTL14 is linked to hepatocellular carcinoma.